SION

Sionna Therapeutics Inc

5.87

Aug 28 • 3:59 PM ET -0.19 (-3.14%)

5.89

Aftermarket • 6:30 PM ET +0.02 (0.32%)

Healthcare Biotechnology USA Micro NASD

Peers: KYMR CRNX RYTM VKTX BMRN APGE INCY KRYS AXSM NBIX

| Held by: VTI VXF VTWO XBI IWM VHT IBB IWO VTWG SCHA

Index	RUT
Market Cap	265.40M
Enterprise Value	62.44M
Income	-97.38M
Sales	0.00M
Book/sh	5.88
Cash/sh	4.67
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	59
IPO	Feb 07, 2025

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	1.00
P/C	1.26
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	20.05
Current Ratio	20.05
Debt/Eq	0.03
LT Debt/Eq	0.03
Option/Short	Yes / Yes

EPS (ttm)	-2.17
EPS next Y	-2.55
EPS next Q	-0.63
EPS this Y	-34.53%
EPS next Y	-1.01%
EPS next 5Y	-16.57%
EPS past 3/5Y	-22.66% -
Sales past 3/5Y	- -
EPS Y/Y TTM	-26.18%
Sales Y/Y TTM	-
EPS Q/Q	-61.68%
Sales Q/Q	-
Earnings	Aug 06 BMO
EPS/Sales Surpr.	-1.54% -

Insider Own	41.43%
Insider Trans	-10.26%
Inst Own	70.84%
Inst Trans	9.01%
ROA	-30.66%
ROE	-32.34%
ROIC	-35.74%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-64.94%
SMA50	-82.27%
SMA200	-84.51%
Trades

Shs Outstand	45.16M
Shs Float	26.48M
Short Float	16.04%
Short Ratio	2.39
Short Interest	4.25M
52W High	54.97 -89.32%
52W Low	4.01 46.38%
Volatility	7.66% 11.27%
ATR (14)	2.72
RSI (14)	23.51
Beta	0.67
Rel Volume	0.44
Avg Volume	1.78M
Volume	783,214

Perf Week	10.96%
Perf Month	-87.45%
Perf Quarter	-86.29%
Perf Half Y	-83.94%
Perf YTD	-85.73%
Perf Year	-77.18%
Perf 3Y	-
Perf 5Y	-
Perf 10Y	-
Recom	2.82
Target Price	21.43
Prev Close	6.06
Price	5.87
Change %	-3.14%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-10-26	Upgrade	RBC Capital Mkts	Underperform → Sector Perform	$5
Aug-10-26	Downgrade	Wedbush	Outperform → Neutral	$5
Aug-10-26	Downgrade	Stifel	Buy → Hold	$7
Aug-10-26	Downgrade	Raymond James	Strong Buy → Mkt Perform
Aug-10-26	Downgrade	Guggenheim	Buy → Neutral
Aug-10-26	Downgrade	Citizens	Mkt Outperform → Mkt Perform
Aug-10-26	Downgrade	BTIG Research	Buy → Neutral
May-05-26	Initiated	Wedbush	Outperform	$53
Feb-24-26	Initiated	Citizens	Mkt Outperform	$63
Dec-01-25	Downgrade	RBC Capital Mkts	Sector Perform → Underperform	$24
Nov-19-25	Initiated	BTIG Research	Buy	$50
Sep-03-25	Initiated	RBC Capital Mkts	Sector Perform	$22
Sep-03-25	Initiated	Raymond James	Strong Buy	$45
Mar-04-25	Initiated	TD Cowen	Buy
Mar-04-25	Initiated	Stifel	Buy	$32
Mar-04-25	Initiated	Guggenheim	Buy	$45

Show Previous Ratings

Aug-19-26 10:22PM	Robbins LLP Reminds Stockholders it is Investigating the Recent Stock Drop of Sionna Therapeutics (PR Newswire) +5.22% -11.68%
Aug-17-26 04:20PM	Robbins LLP is Investigating the Recent Stock Drop of Sionna Therapeutics; Contact the Firm for Information (Business Wire) -8.51%
Aug-11-26 09:11AM	Sionna Therapeutics stock falls 92% after SION-719 trial failure (Quartz) +13.33%
Aug-10-26 04:36PM	Immunic appoints Elena Ridloff to board of directors (Proactive) -91.18%
03:14PM	Why Sionna Therapeutics Stock Is Crashing 91% to a Record Low (Barrons.com)
01:18PM	Loading…
01:18PM	SION Stock On Track For Worst Day Ever After 90% Drop Whats Driving The Selloff? (Stocktwits)
11:55AM	Vertex Stock Jumps 5.9% as Rival Cystic Fibrosis Drug Fails (GuruFocus.com)
10:52AM	Tenax, Sionna Shares Sink After Trial Failures (The Wall Street Journal)
08:48AM	Sionna Therapeutics shares collapse 92% after cystic fibrosis trial misses key endpoint (InvestorsHub)
08:25AM	Tenax, Sionna plunge; MarineMax jumps premarket on reported buyout (Investing.com)
07:00AM	Sionna Therapeutics Reports Topline Data from Two Development Programs in Cystic Fibrosis and Provides Corporate Update (GlobeNewswire)
Aug-06-26 07:00AM	Sionna Therapeutics Reports Second Quarter 2026 Financial Results (GlobeNewswire)
May-27-26 08:00AM	Sionna Therapeutics to Participate in Upcoming June 2026 Investor Conferences (GlobeNewswire)
May-13-26 08:00AM	Sionna Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference (GlobeNewswire) +5.32%
May-12-26 07:00AM	Sionna Therapeutics Reports First Quarter 2026 Financial Results (GlobeNewswire) -10.90%
07:00AM	Loading…
Apr-27-26 07:00AM	Sionna Therapeutics Completes Enrollment in PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, Added to Standard of Care in Participants with Cystic Fibrosis (GlobeNewswire)
Apr-07-26 07:00AM	Sionna Therapeutics to Participate in the Raymond James 2026 Biotech Innovation Symposium (GlobeNewswire)
Mar-02-26 07:00AM	Sionna Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire) -7.17%
Feb-23-26 08:00AM	Sionna Therapeutics to Participate in Upcoming March 2026 Investor Conferences (GlobeNewswire)
Feb-15-26 04:41AM	Sionna Therapeutics Maps Mid-2026 CF Catalysts, Highlights NBD1 Stabilizers at Guggenheim Summit (MarketBeat)
Feb-04-26 07:00AM	Sionna Therapeutics to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 (GlobeNewswire) -7.12%
Jan-05-26 07:00AM	Sionna Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-23-25 09:33AM	Coty downgraded, Spruce Biosciences initiated: Wall Street's top analyst calls (The Fly)
Nov-24-25 07:00AM	Sionna Therapeutics to Participate in Upcoming December Investor Conferences (GlobeNewswire)
Nov-14-25 06:00PM	Bitdeer, Pacira BioSciences, Garrett Motion, and More Stocks See Action From Activist Investors (Barrons.com) +7.92%
Nov-05-25 07:00AM	Sionna Therapeutics Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Nov-04-25 08:00AM	Sionna Therapeutics to Participate in Upcoming November Investor Conferences (GlobeNewswire)
Oct-31-25 05:42PM	Astria, Viridian Therapeutics, and More Stocks See Action From Activist Investors (Barrons.com) -5.63%
Oct-24-25 01:15PM	Sionna Therapeutics Announces Presentation of SION-719 and SION-451 Phase 1 Data and Poster of New Preclinical Data on the Impact of NBD1 Stabilizers on F508del-CFTR Half-Life at the 2025 North American Cystic Fibrosis Conference (GlobeNewswire)
Oct-21-25 07:00AM	Sionna Therapeutics Announces Initiation of PreciSION CF Phase 2a Trial Evaluating NBD1 Stabilizer, SION-719, When Added to Standard of Care in Participants with Cystic Fibrosis (GlobeNewswire) +31.99%
04:05PM	Loading…
Oct-01-25 04:05PM	Sionna Therapeutics to Present Data at the 2025 North American Cystic Fibrosis Conference (GlobeNewswire)
Sep-15-25 12:00PM	All You Need to Know About Sionna Therapeutics, Inc. (SION) Rating Upgrade to Buy (Zacks)
Sep-09-25 09:55AM	Wall Street Analysts See a 66.51% Upside in Sionna Therapeutics, Inc. (SION): Can the Stock Really Move This High? (Zacks) +13.32%
Sep-08-25 08:00AM	Sionna Therapeutics Appoints Caroline Stark Beer as Chief Business Officer (GlobeNewswire) -9.92%
Aug-27-25 07:00AM	Sionna Therapeutics to Participate in Upcoming September Investor Conferences (GlobeNewswire)
Aug-25-25 07:00AM	Sionna Therapeutics Announces First Subjects Dosed in Phase 1 Trial Evaluating NBD1 Stabilizer, SION-451, in Proprietary Dual Combinations in Development for the Treatment of Cystic Fibrosis (GlobeNewswire)
Aug-11-25 07:00AM	Sionna Therapeutics Reports Second Quarter 2025 Financial Results (GlobeNewswire) +13.36%
Jun-06-25 11:00AM	Sionna Therapeutics Announces Presentation of Preclinical Data that Demonstrate Proprietary Dual Combination Therapies Enable Full CFTR Correction in CFHBE Model (GlobeNewswire) +7.42%
Jun-04-25 01:54PM	Newly-Listed Sionna Therapeutics Touts Positive Data From Lung Disease Candidate In Healthy Volunteer Trial (Benzinga) +9.12%
07:00AM	Sionna Therapeutics Announces Positive Phase 1 Data for NBD1 Stabilizers SION-719 and SION-451 and Advances Both Programs in Clinical Development for Cystic Fibrosis (GlobeNewswire)
Jun-03-25 07:00AM	Sionna Therapeutics to Present at the Goldman Sachs 46th Annual Global Healthcare Conference (GlobeNewswire)
May-22-25 07:00AM	Sionna Therapeutics to Present Preclinical Data During Oral Session at the 48th European Cystic Fibrosis Conference (GlobeNewswire)
May-12-25 07:00AM	Sionna Therapeutics Reports First Quarter 2025 Financial Results (GlobeNewswire)
Apr-30-25 07:00AM	Sionna Therapeutics to Present at The Citizens Life Sciences Conference 2025 (GlobeNewswire)
Mar-20-25 07:00AM	Sionna Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Mar-15-25 04:43PM	Sionna Therapeutics, Inc. (SION): Among Top Insider Purchases Last Month (Insider Monkey)
Mar-06-25 10:25AM	Is Sionna Therapeutics, Inc. (SION) Among Stocks With At Least $20 Million In Insider Spending Recently? (Insider Monkey) -5.04%
Mar-03-25 12:57PM	Sionna Therapeutics, Inc. (SION): Among Stocks With At Least $10 Million In Insider Spending Recently (Insider Monkey)
Feb-25-25 05:56AM	Sionna Therapeutics IPO: A strategic shift in the cystic fibrosis market (Pharmaceutical Technology) -13.37%
Feb-24-25 08:00AM	Sionna Therapeutics to Present at the 45th Annual TD Cowen Health Care Conference (GlobeNewswire)
Feb-17-25 04:43PM	Is Sionna Therapeutics (SION) Among Stocks Insiders Are Buying This Year? (Insider Monkey)
Feb-10-25 04:03PM	Sionna Therapeutics Announces Closing of $219.2 million Upsized Initial Public Offering, Including Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire) -11.04% -8.23%
Feb-06-25 07:51PM	Sionna Therapeutics Prices Upsized Initial Public Offering (GlobeNewswire)
03:13PM	Vertex challenger Sionna prices $191M IPO (BioPharma Dive)

Sionna Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. The firm engages in researching, developing and commercializing novel medicines for cystic fibrosis. It is focused on advancing a pipeline of small molecules and complementary CFTR modulators designed to deliver transformative clinical outcomes and improve the quality of life for individuals living with cystic fibrosis. The company was founded by Greg Hurlbut and Mark Munson in August 2019 and is headquartered in Waltham, MA.

PresidentMr. Michael Cloonan M.B.A.

Chief Financial OfficerMs. Elena H. Ridloff C.F.A.

Chief Business OfficerMs. Caroline Stark Beer M.B.A.

Co-Founder & Senior VP of Discovery ResearchDr. Greg Hurlbut Ph.D.

Co-founder & Senior VP of Medicinal ChemistryDr. Mark Munson Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Thompson Peter A.	Director	Jul 07 '26	Sale	44.86	85,918	3,854,281	2,469,959	Jul 09 04:47 PM
ORBIMED ADVISORS LLC	Director	Jul 07 '26	Sale	44.86	85,918	3,854,281	2,469,959	Jul 09 04:44 PM
Fitzpatrick Jennifer	Chief Legal Officer	Jul 06 '26	Option Exercise	6.11	10,250	62,628	10,250	Jul 07 04:38 PM
Fitzpatrick Jennifer	Chief Legal Officer	Jul 06 '26	Sale	43.60	10,250	446,862	0	Jul 07 04:38 PM
JENNIFER FITZPATRICK	Officer	Jul 06 '26	Proposed Sale	43.99	10,250	450,898		Jul 06 04:39 PM
Thompson Peter A.	Director	Jun 30 '26	Sale	45.50	115,844	5,270,902	2,555,877	Jul 02 04:45 PM
ORBIMED ADVISORS LLC	Director	Jun 30 '26	Sale	45.50	115,844	5,270,902	2,555,877	Jul 02 04:42 PM
Thompson Peter A.	Director	May 27 '26	Sale	44.49	101	4,493	2,671,721	May 29 09:02 PM
ORBIMED ADVISORS LLC	Director	May 27 '26	Sale	44.49	101	4,493	2,671,721	May 29 08:57 PM
OrbiMed Private Investments VI	Shareholder	May 29 '26	Proposed Sale	42.80	1,082,480	46,330,144		May 29 06:44 PM
Thompson Peter A.	Director	May 11 '26	Sale	46.22	184,639	8,534,015	2,671,822	May 11 07:14 PM
Thompson Peter A.	Director	May 08 '26	Sale	44.58	59,767	2,664,413	2,856,461	May 11 07:14 PM
Thompson Peter A.	Director	May 07 '26	Sale	44.61	48,546	2,165,637	2,916,228	May 11 07:14 PM
ORBIMED ADVISORS LLC	Director	May 11 '26	Sale	46.22	184,639	8,534,015	2,671,822	May 11 06:58 PM
ORBIMED ADVISORS LLC	Director	May 08 '26	Sale	44.58	59,767	2,664,413	2,856,461	May 11 06:58 PM
ORBIMED ADVISORS LLC	Director	May 07 '26	Sale	44.61	48,546	2,165,637	2,916,228	May 11 06:58 PM
Thompson Peter A.	Director	Apr 17 '26	Sale	44.68	52,397	2,341,098	2,967,722	Apr 21 08:42 PM
Thompson Peter A.	Director	Apr 18 '26	Sale	44.52	2,948	131,245	2,964,774	Apr 21 08:42 PM
ORBIMED ADVISORS LLC	Director	Apr 17 '26	Sale	44.68	52,397	2,341,098	2,967,722	Apr 21 08:40 PM
ORBIMED ADVISORS LLC	Director	Apr 18 '26	Sale	44.52	2,948	131,245	2,964,774	Apr 21 08:40 PM
Thompson Peter A.	Director	Apr 15 '26	Sale	44.64	235,863	10,528,924	3,247,025	Apr 16 07:15 PM
Thompson Peter A.	Director	Apr 16 '26	Sale	45.34	226,906	10,287,918	3,020,119	Apr 16 07:15 PM
Thompson Peter A.	Director	Apr 14 '26	Sale	44.51	47,814	2,128,201	3,482,888	Apr 16 07:15 PM
ORBIMED ADVISORS LLC	Director	Apr 15 '26	Sale	44.64	235,863	10,528,924	3,247,025	Apr 16 07:03 PM
ORBIMED ADVISORS LLC	Director	Apr 16 '26	Sale	45.34	226,906	10,287,918	3,020,119	Apr 16 07:03 PM
ORBIMED ADVISORS LLC	Director	Apr 14 '26	Sale	44.51	47,814	2,128,201	3,482,888	Apr 16 07:03 PM
Fitzpatrick Jennifer	Chief Legal Officer	Mar 05 '26	Option Exercise	6.11	10,250	62,628	10,250	Mar 06 06:56 PM
Fitzpatrick Jennifer	Chief Legal Officer	Mar 05 '26	Sale	33.86	10,250	347,019	0	Mar 06 06:56 PM
JENNIFER FITZPATRICK	Officer	Mar 05 '26	Proposed Sale	34.57	10,250	354,342		Mar 05 04:28 PM
Thompson Peter A.	Director	Feb 03 '26	Sale	44.58	29,063	1,295,629	3,530,702	Feb 04 07:43 PM
Thompson Peter A.	Director	Feb 02 '26	Sale	44.57	1,890	84,237	3,559,765	Feb 04 07:43 PM
ORBIMED ADVISORS LLC	Director	Feb 03 '26	Sale	44.58	29,063	1,295,629	3,530,702	Feb 04 07:39 PM
ORBIMED ADVISORS LLC	Director	Feb 02 '26	Sale	44.57	1,890	84,237	3,559,765	Feb 04 07:39 PM
TPG GP A, LLC	10% Owner	Jan 22 '26	Sale	40.00	250,000	10,000,000	6,494,962	Jan 26 05:24 PM
Rise Fund Sling, L.P.	Stockholder	Jan 22 '26	Proposed Sale	41.77	195,667	8,173,011		Jan 22 08:47 PM
Rise Fund Sling II, L.P.	Stockholder	Jan 22 '26	Proposed Sale	41.77	54,333	2,269,489		Jan 22 08:47 PM
ORBIMED ADVISORS LLC	Director	Dec 24 '25	Sale	44.55	33,356	1,486,010	3,561,655	Dec 29 08:44 PM
Thompson Peter A.	Director	Dec 24 '25	Sale	44.55	33,356	1,486,010	3,561,655	Dec 29 08:42 PM
ORBIMED ADVISORS LLC	Director	Dec 17 '25	Sale	44.50	900	40,050	3,595,986	Dec 19 07:29 PM
ORBIMED ADVISORS LLC	Director	Dec 19 '25	Sale	44.49	875	38,929	3,595,011	Dec 19 07:29 PM
ORBIMED ADVISORS LLC	Director	Dec 18 '25	Sale	44.49	100	4,449	3,595,886	Dec 19 07:29 PM
Thompson Peter A.	Director	Dec 17 '25	Sale	44.50	900	40,050	3,595,986	Dec 19 07:24 PM
Thompson Peter A.	Director	Dec 19 '25	Sale	44.49	875	38,929	3,595,011	Dec 19 07:24 PM
Thompson Peter A.	Director	Dec 18 '25	Sale	44.49	100	4,449	3,595,886	Dec 19 07:24 PM
Fitzpatrick Jennifer	Chief Legal Officer	Dec 05 '25	Option Exercise	6.11	10,250	62,628	10,250	Dec 09 04:57 PM
Fitzpatrick Jennifer	Chief Legal Officer	Dec 05 '25	Sale	40.52	10,250	415,330	0	Dec 09 04:57 PM
JENNIFER R FITZPATRICK	Officer	Dec 05 '25	Proposed Sale	40.88	10,250	419,020		Dec 05 04:27 PM
ORBIMED ADVISORS LLC	Director	Nov 24 '25	Sale	44.54	94,583	4,212,727	3,610,376	Nov 26 06:45 PM
ORBIMED ADVISORS LLC	Director	Nov 25 '25	Sale	44.60	11,890	530,294	3,598,486	Nov 26 06:45 PM
ORBIMED ADVISORS LLC	Director	Nov 26 '25	Sale	44.49	1,600	71,184	3,596,886	Nov 26 06:45 PM
Thompson Peter A.	Director	Nov 24 '25	Sale	44.54	94,583	4,212,727	3,610,376	Nov 26 06:41 PM
Thompson Peter A.	Director	Nov 25 '25	Sale	44.60	11,890	530,294	3,598,486	Nov 26 06:41 PM
Thompson Peter A.	Director	Nov 26 '25	Sale	44.49	1,600	71,184	3,596,886	Nov 26 06:41 PM
OrbiMed Private Investments VI	Shareholder	Nov 24 '25	Proposed Sale	44.38	1,047,770	46,500,033		Nov 24 08:22 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Nov 21 '25	Sale	39.50	25,183	994,728	159,033	Nov 24 05:43 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Nov 20 '25	Sale	40.13	5,133	205,975	166,642	Nov 24 05:43 PM
RA Capital Healthcare Fund LP	Director	Nov 21 '25	Proposed Sale	43.66	1,210	52,829		Nov 21 04:24 PM
RA Capital Nexus Fund III, L.P	Director	Nov 21 '25	Proposed Sale	43.66	6,440	281,170		Nov 21 04:21 PM
RA Capital Nexus Fund, L.P.	Director	Nov 21 '25	Proposed Sale	43.66	9,924	433,282		Nov 21 04:19 PM
BLACKWELL PARTNERS LLC - SERIE	Director	Nov 21 '25	Proposed Sale	43.66	7,609	332,209		Nov 21 04:17 PM
RA Capital Nexus Fund III, L.P	Director	Nov 20 '25	Proposed Sale	38.94	1,313	51,128		Nov 20 04:40 PM
RA Capital Nexus Fund, L.P.	Director	Nov 20 '25	Proposed Sale	38.94	2,023	78,776		Nov 20 04:35 PM
RA Capital Healthcare Fund LP	Director	Nov 20 '25	Proposed Sale	38.94	246	9,579		Nov 20 04:34 PM
BLACKWELL PARTNERS LLC - SERIE	Director	Nov 20 '25	Proposed Sale	38.94	1,551	60,396		Nov 20 04:30 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Nov 17 '25	Sale	40.59	81,987	3,328,081	184,619	Nov 19 08:43 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Nov 19 '25	Sale	40.01	47,442	1,898,173	168,193	Nov 19 08:43 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Nov 18 '25	Sale	39.57	6,922	273,904	182,527	Nov 19 08:43 PM
RA Capital Healthcare Fund LP	Director	Nov 19 '25	Proposed Sale	39.12	2,278	89,115		Nov 19 05:21 PM
BLACKWELL PARTNERS LLC - SERIE	Director	Nov 19 '25	Proposed Sale	38.41	14,334	550,568		Nov 19 05:16 PM
RA Capital Nexus Fund, L.P.	Director	Nov 19 '25	Proposed Sale	38.41	18,696	718,113		Nov 19 05:10 PM
RA Capital Nexus Fund III, L.P	Director	Nov 19 '25	Proposed Sale	38.41	12,134	466,066		Nov 19 05:04 PM
BLACKWELL PARTNERS LLC - SERIE	Director	Nov 18 '25	Proposed Sale	39.04	2,092	81,671		Nov 18 05:22 PM
RA Capital Nexus Fund, L.P.	Director	Nov 18 '25	Proposed Sale	39.04	2,728	106,501		Nov 18 05:17 PM
RA Capital Nexus Fund III, L.P	Director	Nov 18 '25	Proposed Sale	39.04	1,770	69,100		Nov 18 05:09 PM
RA Capital Healthcare Fund LP	Director	Nov 18 '25	Proposed Sale	39.04	332	12,961		Nov 18 04:58 PM
BLACKWELL PARTNERS LLC - SERIE	Director	Nov 17 '25	Proposed Sale	39.93	24,772	989,146		Nov 17 05:12 PM
RA Capital Nexus Fund, L.P.	Director	Nov 17 '25	Proposed Sale	39.93	32,310	1,290,138		Nov 17 05:04 PM
RA Capital Nexus Fund III, L.P	Director	Nov 17 '25	Proposed Sale	39.93	20,969	837,292		Nov 17 04:56 PM
RA Capital Healthcare Fund LP	Director	Nov 17 '25	Proposed Sale	39.93	3,936	157,164		Nov 17 04:46 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Oct 24 '25	Sale	39.50	311,000	12,284,500	219,867	Oct 28 09:05 PM
RA CAPITAL MANAGEMENT, L.P.	Director	Oct 28 '25	Sale	39.58	62,610	2,478,104	209,391	Oct 28 09:05 PM
RA Capital Nexus Fund III, L.P	Director	Oct 28 '25	Proposed Sale	39.45	17,118	675,305		Oct 28 05:13 PM
RA Capital Healthcare Fund LP	Director	Oct 28 '25	Proposed Sale	39.45	3,624	142,967		Oct 28 05:07 PM
RA Capital Nexus Fund, L.P.	Director	Oct 28 '25	Proposed Sale	39.45	31,392	1,238,414		Oct 28 05:05 PM
BLACKWELL PARTNERS LLC - SERIE	Director	Oct 28 '25	Proposed Sale	39.45	10,476	413,278		Oct 28 04:57 PM
RA Capital Nexus Fund, L.P.	Director	Oct 24 '25	Proposed Sale	39.21	122,271	4,794,246		Oct 24 06:05 PM
RA Capital Nexus Fund III, L.P	Director	Oct 24 '25	Proposed Sale	39.21	66,672	2,614,209		Oct 24 06:00 PM
RA Capital Healthcare Fund LP	Director	Oct 24 '25	Proposed Sale	39.21	14,116	553,488		Oct 24 05:53 PM
BLACKWELL PARTNERS LLC - SERIE	Director	Oct 24 '25	Proposed Sale	39.21	107,941	4,232,367		Oct 24 05:39 PM
Cloonan Michael	President & CEO	Oct 21 '25	Option Exercise	6.11	99,800	609,778	580,875	Oct 22 05:39 PM
Cloonan Michael	President & CEO	Oct 21 '25	Sale	36.26	99,800	3,618,560	547,343	Oct 22 05:39 PM
Booth Bruce	Director	Oct 21 '25	Sale	34.22	88,878	3,041,683	686,567	Oct 21 05:12 PM
Atlas Venture Opportunity Fund	Shareholder	Oct 21 '25	Proposed Sale	32.20	15,418	496,460		Oct 21 04:22 PM
Atlas Venture Fund XI, LP	Shareholder	Oct 21 '25	Proposed Sale	32.20	73,460	2,365,412		Oct 21 04:21 PM
MICHAEL CLOONAN	Director	Oct 21 '25	Proposed Sale	32.20	99,800	3,213,560		Oct 21 04:19 PM
Booth Bruce	Director	Oct 16 '25	Sale	32.35	169,260	5,476,168	722,301	Oct 20 09:39 PM
Booth Bruce	Director	Oct 17 '25	Sale	32.37	61,124	1,978,323	711,697	Oct 20 09:39 PM
Booth Bruce	Director	Oct 20 '25	Sale	32.09	55,985	1,796,611	701,985	Oct 20 09:39 PM
Atlas Venture Fund XI, LP	Shareholder	Oct 20 '25	Proposed Sale	31.93	46,273	1,477,497		Oct 20 04:46 PM
Atlas Venture Opportunity Fund	Shareholder	Oct 20 '25	Proposed Sale	31.93	9,712	310,104		Oct 20 04:46 PM

Open in Screener

CRVS

Corvus Pharmaceuticals Inc

14.16

Aug 28 • 3:59 PM ET -0.56 (-3.80%)

14.16

Aftermarket • 5:00 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Small NASD

CRVS Corvus Pharmaceuticals Inc daily Stock Chart

Peers: IDYA RCUS CGON KYMR TNGX CRNX RYTM INCY KRYS BMRN

| Held by: XBI VTI IWM VXF IWO IBB VTWO IWC USVM VHT

Index	RUT
Market Cap	1.19B
Enterprise Value	976.65M
Income	-54.13M
Sales	0.00M
Book/sh	2.68
Cash/sh	2.56
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	37
IPO	Mar 23, 2016

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	5.29
P/C	5.53
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	16.16
Current Ratio	16.16
Debt/Eq	0.00
LT Debt/Eq	0.00
Option/Short	Yes / Yes

EPS (ttm)	-0.62
EPS next Y	-0.93
EPS next Q	-0.19
EPS this Y	-293.49%
EPS next Y	-24.31%
EPS next 5Y	-
EPS past 3/5Y	15.40% -21.44%
Sales past 3/5Y	- -
EPS Y/Y TTM	8.13%
Sales Y/Y TTM	-
EPS Q/Q	-89.11%
Sales Q/Q	-
Earnings	Aug 06 AMC
EPS/Sales Surpr.	-19.42% -

Insider Own	22.98%
Insider Trans	0.15%
Inst Own	66.26%
Inst Trans	0.84%
ROA	-32.93%
ROE	-35.43%
ROIC	-23.99%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-1.92%
SMA50	-0.60%
SMA200	3.72%
Trades

Shs Outstand	84.12M
Shs Float	64.79M
Short Float	29.52%
Short Ratio	16.75
Short Interest	19.13M
52W High	26.95 -47.46%
52W Low	5.28 168.18%
Volatility	3.79% 4.83%
ATR (14)	0.72
RSI (14)	47.77
Beta	0.87
Rel Volume	0.56
Avg Volume	1.14M
Volume	644,531

Perf Week	-2.07%
Perf Month	7.35%
Perf Quarter	14.10%
Perf Half Y	-22.45%
Perf YTD	83.90%
Perf Year	161.74%
Perf 3Y	597.54%
Perf 5Y	540.72%
Perf 10Y	0.35%
Recom	1.12
Target Price	33.14
Prev Close	14.72
Price	14.16
Change %	-3.80%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-17-26	Initiated	Goldman	Buy	$40
Oct-13-25	Initiated	Barclays	Overweight	$16
Jan-02-25	Initiated	H.C. Wainwright	Buy	$11
Aug-18-23	Initiated	Oppenheimer	Outperform	$7
Dec-01-21	Resumed	Jefferies	Buy	$8
May-27-21	Initiated	Cantor Fitzgerald	Overweight	$10
Feb-10-21	Downgrade	Mizuho	Buy → Neutral	$7 → $4
Sep-12-19	Initiated	Mizuho	Buy
May-29-19	Initiated	ROTH Capital	Buy	$6
Aug-24-17	Upgrade	Credit Suisse	Underperform → Neutral
May-01-17	Downgrade	Credit Suisse	Neutral → Underperform
Apr-18-16	Initiated	Guggenheim	Buy
Apr-18-16	Initiated	Credit Suisse	Outperform

Show Previous Ratings

Aug-27-26 07:30AM	Corvus Pharmaceuticals Announces Publication in Blood of Final Phase 1 Data from the Soquelitinib Phase 1/1b T Cell Lymphoma Trial (GlobeNewswire)
Aug-07-26 01:09AM	Corvus Pharmaceuticals Inc (CRVS) (Q2 2026) Earnings Call Highlights: Advancing Soquelitinib ... (GuruFocus.com)
Aug-06-26 11:43PM	Corvus Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary (Moby)
04:36PM	Corvus: Q2 Earnings Snapshot (Associated Press)
04:01PM	Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2026 Financial Results (GlobeNewswire)
04:01PM	Loading…
Jul-30-26 04:01PM	Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2026 Financial Results on August 6, 2026 (GlobeNewswire)
Jun-09-26 07:30AM	Corvus Pharmaceuticals Announces Additional Investment in Angel Pharmaceuticals to Advance the Development of Soquelitinib in China (GlobeNewswire)
May-20-26 04:01PM	Corvus Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference and Goldman Sachs 47th Annual Global Healthcare Conference (GlobeNewswire) +6.00% +7.30%
May-14-26 07:00AM	Corvus Pharmaceuticals Presents Soquelitinib Phase 1 Atopic Dermatitis Data at the Society for Investigative Dermatology (SID) Annual Meeting (GlobeNewswire) -13.79%
May-07-26 04:44PM	Corvus: Q1 Earnings Snapshot (Associated Press) -5.57% +6.58%
04:01PM	Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2026 Financial Results (GlobeNewswire)
Apr-23-26 07:30AM	Corvus Pharmaceuticals Appoints Andrew C. Chan, M.D., Ph.D., to Board of Directors (GlobeNewswire) -10.25%
Apr-21-26 07:30AM	Corvus Pharmaceuticals to Host Investor and Analyst Meeting on May 14, 2026 to Highlight Soquelitinib Data Being Presented at the Society for Investigative Dermatology (SID) Annual Meeting (GlobeNewswire) +10.30%
Apr-17-26 09:36AM	Apple upgraded, Qualcomm downgraded: Wall Street's top analyst calls (The Fly) +11.30%
Mar-13-26 08:30AM	Corvus Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary (Moby)
11:07PM	Loading…
Mar-12-26 11:07PM	Corvus Pharmaceuticals Inc (CRVS) Q4 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com) -5.27%
04:08PM	Corvus: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Mar-05-26 04:01PM	Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2025 Financial Results on March 12, 2026 (GlobeNewswire) -9.98%
Feb-27-26 12:39PM	Corvus Pharmaceuticals Highlights Soquelitinib Pipeline, Eyes Phase II Atopic Dermatitis Trial in 2026 (MarketBeat)
Feb-23-26 04:01PM	Corvus Pharmaceuticals to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Feb-02-26 10:39AM	Momentum Is Just Starting for These 3 Rapid-Growth Stocks in 2026 (MarketBeat)
Jan-27-26 12:15PM	Corvus Pharmaceuticals Stock Rallies 209% in a Month: Here's Why (Zacks)
12:00PM	Corvus Pharmaceuticals (CRVS) Is Up 211.80% in One Week: What You Should Know (Zacks)
09:55AM	Wall Street Analysts Think Corvus (CRVS) Could Surge 25.29%: Read This Before Placing a Bet (Zacks)
05:03AM	Corvus Pharmaceuticals (CRVS) Falls on Profit-Taking After 212% Jump (Insider Monkey)
Jan-25-26 07:47PM	Corvus Pharmaceuticals (CRVS) Soars 212% on Impressive Eczema Therapy Study (Insider Monkey)
Jan-23-26 05:00PM	Corvus Pharmaceuticals Announces Closing of Upsized Public Offering of Common Stock and Full Exercise of the Underwriters' Option to Purchase Additional Shares, Generating Gross Proceeds of Approximately $201M (GlobeNewswire) -8.33%
08:11AM	Corvus Pharmaceuticals (CRVS) Hits All-Time High on Eczema Trial Results (Insider Monkey)
03:01AM	Corvus Pharmaceuticals Shares New Phase I Soquelitinib Data Showing Strong AD EASI Gains (MarketBeat)
10:53PM	Loading…
Jan-21-26 10:53PM	Corvus Pharmaceuticals Announces Pricing of Upsized Public Offering of Common Stock (GlobeNewswire) +15.21%
06:39AM	Corvus shares nearly triple on positive data for eczema pill (BioPharma Dive)
Jan-20-26 04:08PM	Why Small Biotech Stock Corvus Pharma Just Launched To A Nine-Year High (Investor's Business Daily) +165.96%
04:01PM	Corvus Pharmaceuticals Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire)
02:00PM	Corvus Stock Spikes On Heels Of Strong Eczema Study Results (Benzinga)
07:00AM	Corvus Pharmaceuticals Announces Positive Data from Cohort 4 Confirming Results for Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis (GlobeNewswire)
Jan-16-26 04:01PM	Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis (GlobeNewswire) +12.75%
Jan-05-26 08:30AM	Corvus Pharmaceuticals Confirms Plans to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis in January 2026 Following Annual Healthcare Conference (GlobeNewswire) -7.24%
Dec-08-25 10:30AM	Corvus Pharmaceuticals Presents Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial (GlobeNewswire)
Nov-04-25 04:51PM	Corvus: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Nov-03-25 09:02AM	Corvus Pharmaceuticals to Present Final Data from Soquelitinib Phase 1/1b T Cell Lymphoma Trial at the 67th American Society of Hematology Annual Meeting & Exposition (GlobeNewswire)
Oct-31-25 07:30AM	Corvus Pharmaceuticals to Present at the Guggenheim 2nd Annual Healthcare Innovation Conference (GlobeNewswire)
Oct-28-25 04:01PM	Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2025 Financial Results on November 4, 2025 (GlobeNewswire)
Oct-17-25 10:00AM	Corvus Pharmaceuticals Announces Presentation of Interim Data from the Phase 1b/2 Clinical Trial of Ciforadenant for Patients with Metastatic Renal Cell Cancer at the European Society for Medical Oncology (ESMO) Congress 2025 (GlobeNewswire) -7.97%
Oct-02-25 04:01PM	Corvus Pharmaceuticals Appoints David Moore to Board of Directors (GlobeNewswire)
Aug-07-25 04:17PM	Corvus: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-01-25 09:00AM	BioMarin Announces Appointment of Ian T. Clark to Board of Directors (PR Newswire)
Jul-31-25 04:01PM	Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2025 Financial Results on August 7, 2025 (GlobeNewswire)
Jun-25-25 08:00AM	Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for a Phase 1b/2 Clinical Trial of Soquelitinib in China for the Treatment of Atopic Dermatitis (GlobeNewswire) -5.07%
Jun-11-25 07:00AM	Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data Highlighting Potential of ITK inhibition to Treat Systemic Sclerosis at EULAR 2025 Congress (GlobeNewswire) +5.88%
Jun-04-25 07:00AM	Corvus Pharmaceuticals Announces Full Data from Cohort 3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis (GlobeNewswire) -8.98%
May-28-25 04:01PM	Corvus Pharmaceuticals to Present at the 2025 Jefferies Global Healthcare Conference (GlobeNewswire)
May-09-25 08:32AM	Is Corvus Pharmaceuticals, Inc. (CRVS) the Low Risk High Reward Stock Set to Triple by 2030? (Insider Monkey) +32.24%
03:41AM	Corvus Pharmaceuticals Inc (CRVS) Q1 2025 Earnings Call Highlights: A Turnaround with Promising ... (GuruFocus.com)
May-08-25 04:39PM	Corvus: Q1 Earnings Snapshot (Associated Press Finance)
04:02PM	Corvus Pharmaceuticals Provides Business Update and Reports First Quarter 2025 Financial Results (GlobeNewswire)
04:01PM	Corvus Pharmaceuticals Announces Data from Cohorts 1-3 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis (GlobeNewswire)
May-07-25 05:35PM	Corvus Pharmaceuticals Q1 2025 Earnings Preview (Seeking Alpha)
Apr-23-25 04:08PM	Corvus Pharmaceuticals to Present New Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on May 8, 2025 (GlobeNewswire) +5.71%
Apr-22-25 06:47PM	Is Corvus Pharmaceuticals, Inc. (CRVS) the Best Multibagger Penny Stock to Buy According to Billionaires? (Insider Monkey)
Apr-09-25 04:01PM	Corvus Pharmaceuticals Appoints Richard A. van den Broek to Board of Directors (GlobeNewswire)
Mar-28-25 09:30AM	Corvus Pharmaceuticals' Short Runway Overshadows Soquelitinib's Promising Trials (Seeking Alpha)
09:29AM	Corvus Pharmaceuticals: Now At Cruising Altitude (Seeking Alpha)
Mar-26-25 10:39AM	Q4 2024 Corvus Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -14.76%
03:02AM	Corvus Pharmaceuticals Inc (CRVS) Q4 2024 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
Mar-25-25 07:58PM	Corvus Pharmaceuticals, Inc. (CRVS) Q4 2024 Earnings Call Transcript (SeekingAlpha) -7.53%
04:09PM	Corvus: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Mar-20-25 08:00AM	Corvus Pharmaceuticals Announces Presentation of Additional Data from the Phase 1/1b Clinical Trial of Soquelitinib for Patients with T Cell Lymphoma (GlobeNewswire)
Mar-19-25 04:01PM	Corvus Pharmaceuticals to Present at the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference (GlobeNewswire) -5.76%
Mar-17-25 04:01PM	Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025 (GlobeNewswire)
Mar-12-25 08:00AM	Corvus Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of Soquelitinib for Patients with Autoimmune Lymphoproliferative Syndrome (ALPS) (GlobeNewswire) +5.95%
Feb-04-25 08:00AM	Corvus Pharmaceuticals to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire) +5.33%
Jan-13-25 07:30AM	Corvus Pharmaceuticals Announces Data from Cohort 2 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis (GlobeNewswire)
Jan-07-25 04:01PM	Corvus Pharmaceuticals to Present at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-18-24 01:23PM	Why Is Corvus Pharmaceuticals Stock Trading Lower On Wednesday? (Benzinga) -36.40%
07:30AM	Corvus Pharmaceuticals Announces Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis (GlobeNewswire)
06:45AM	Tessera gets sickle cell funding; Corvus shares slide on eczema data (BioPharma Dive)
Dec-17-24 04:01PM	Corvus Pharmaceuticals to Announce Interim Data from Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis on December 18, 2024 (GlobeNewswire) +7.10%
Dec-04-24 04:05PM	Corvus Pharmaceuticals Announces Publication of Biochemistry and Preclinical Data Demonstrating Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Modulate Tumor Immunity (GlobeNewswire)
Nov-14-24 10:01AM	Corvus Pharmaceuticals Announces New Preclinical Data Highlighting Potential of Soquelitinib to Treat Systemic Sclerosis (GlobeNewswire)
Nov-13-24 02:18AM	Corvus Pharmaceuticals Inc (CRVS) Q3 2024 Earnings Call Highlights: Strategic Advancements Amid ... (GuruFocus.com)
Nov-12-24 04:13PM	Corvus: Q3 Earnings Snapshot (Associated Press Finance) -9.10%
04:01PM	Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results (GlobeNewswire)
Nov-09-24 01:40PM	Corvus Pharmaceuticals Announces New Data Highlighting Potential of Ciforadenant to Overcome Immunotherapy Resistance in Metastatic Castration Resistant Prostate Cancer (GlobeNewswire)
Nov-05-24 04:02PM	Corvus Pharmaceuticals to Provide Business Update and Third Quarter 2024 Financial Results on November 12, 2024 (GlobeNewswire)
Sep-10-24 08:30AM	Corvus Pharmaceuticals Initiates Registrational Phase 3 Clinical Trial of Soquelitinib for Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma (GlobeNewswire) +13.88%
Sep-03-24 04:05PM	Corvus Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference (GlobeNewswire) -9.82%
Aug-06-24 04:15PM	Corvus: Q2 Earnings Snapshot (Associated Press Finance) +6.38% +9.67%
04:01PM	Corvus Pharmaceuticals Provides Business Update and Reports Second Quarter 2024 Financial Results (GlobeNewswire)
Aug-01-24 08:30AM	Corvus Pharmaceuticals Granted FDA Fast Track Designation for Soquelitinib for Treatment of Patients with Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) (GlobeNewswire) +16.34%
Jul-31-24 08:30AM	Corvus Pharmaceuticals to Provide Business Update and Second Quarter 2024 Financial Results on August 6, 2024 (GlobeNewswire)
Jul-25-24 08:30AM	Publication of Preclinical Data in Science Signaling Demonstrated the Potential of ITK Inhibition with Soquelitinib as a Novel Approach to Treatment of Inflammatory Diseases (GlobeNewswire) +6.45%
May-31-24 10:00AM	The 2024 Millionaire's Club: 3 Penny Stocks to Buy Now (InvestorPlace)
May-30-24 04:02PM	Corvus Pharmaceuticals to Present at the Jefferies Global Health Conference (GlobeNewswire)
May-12-24 03:26PM	13 Penny Stocks with Insider Buying in 2024 (Insider Monkey)
May-07-24 05:12PM	Corvus Pharmaceuticals Insider Bought Shares Worth $1,000,000, According to a Recent SEC Filing (MT Newswires) -12.04% +16.67%
11:07AM	Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q1 2024 Earnings Call Transcript (Insider Monkey)

Corvus Pharmaceuticals, Inc. engages in the development of product candidates for the treatment of cancer and immune-mediated and inflammatory diseases. Its product candidates include soquelitinib, an ITK inhibitor, ciforadenant, an adenosine A2A receptor antagonist, and mupadolimab, a B cell-activating anti-CD73 antibody. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Co-FounderDr. Richard A. Miller M.D.

M.D.Dr. Peter A. Thompson FACP

Chief Financial OfficerMr. Leiv Lea

Senior Vice President of Pharmaceutical DevelopmentDr. William Benton Jones Ph.D.

Senior VP & Chief Business OfficerMr. Jeffrey S. Arcara

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Moore David Scott	Director	Jun 11 '26	Buy	11.53	21,700	250,236	21,700	Jun 15 05:12 PM
MILLER RICHARD A MD	President and CEO	May 18 '26	Buy	12.04	6,932	83,453	1,195,035	May 20 04:12 PM
Thompson Peter A.	Director	Jan 28 '26	Option Exercise	5.33	210,000	1,119,374	210,000	Jan 30 06:39 PM

Open in Screener

EWTX

Edgewise Therapeutics Inc

42.76

Aug 28 • 3:59 PM ET -1.43 (-3.24%)

42.76

Aftermarket • 5:00 PM ET 0.00 (0.00%)

Healthcare Biotechnology USA Mid NASD

EWTX Edgewise Therapeutics Inc daily Stock Chart

Peers: KYMR CRNX RYTM VKTX KRYS BMRN MDGL APGE AXSM NBIX

| Held by: VTI IWM VXF IWO IBB SCHA VTWO IHE DFMC FESM

Index	RUT
Market Cap	4.64B
Enterprise Value	4.19B
Income	-197.22M
Sales	0.00M
Book/sh	4.16
Cash/sh	4.24
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	146
IPO	Mar 26, 2021

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	10.29
P/C	10.08
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	16.24
Current Ratio	16.24
Debt/Eq	0.01
LT Debt/Eq	0.01
Option/Short	Yes / Yes

EPS (ttm)	-1.85
EPS next Y	-1.64
EPS next Q	-0.53
EPS this Y	-26.00%
EPS next Y	20.22%
EPS next 5Y	-4.58%
EPS past 3/5Y	-8.91% -36.19%
Sales past 3/5Y	- -
EPS Y/Y TTM	-18.88%
Sales Y/Y TTM	-
EPS Q/Q	-54.68%
Sales Q/Q	-
Earnings	Aug 06 BMO
EPS/Sales Surpr.	-13.32% -

Insider Own	24.80%
Insider Trans	-1.34%
Inst Own	86.68%
Inst Trans	-0.91%
ROA	-36.09%
ROE	-38.03%
ROIC	-43.76%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-2.61%
SMA50	1.95%
SMA200	31.70%
Trades

Shs Outstand	107.78M
Shs Float	81.67M
Short Float	11.85%
Short Ratio	6.67
Short Interest	9.68M
52W High	48.40 -11.65%
52W Low	13.69 212.46%
Volatility	4.67% 5.21%
ATR (14)	2.23
RSI (14)	48.96
Beta	0.34
Rel Volume	0.51
Avg Volume	1.45M
Volume	739,751

Perf Week	-3.21%
Perf Month	3.99%
Perf Quarter	25.18%
Perf Half Y	40.47%
Perf YTD	72.32%
Perf Year	191.88%
Perf 3Y	518.81%
Perf 5Y	181.50%
Perf 10Y	-
Recom	1.31
Target Price	51.69
Prev Close	44.19
Price	42.76
Change %	-3.24%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-09-26	Initiated	Oppenheimer	Outperform	$51
Sep-25-25	Initiated	Goldman	Neutral	$20
Jul-30-25	Initiated	Raymond James	Strong Buy	$46
Jun-30-25	Initiated	H.C. Wainwright	Buy	$42
Apr-30-25	Initiated	Guggenheim	Buy	$41
Apr-02-25	Downgrade	Scotiabank	Sector Outperform → Sector Perform	$14
Mar-07-25	Initiated	Scotiabank	Sector Outperform	$50
Jan-22-25	Initiated	Stifel	Hold	$30
Nov-22-24	Initiated	Evercore ISI	Outperform	$45
Mar-07-24	Initiated	Piper Sandler	Overweight	$48
May-01-23	Initiated	Truist	Buy
Aug-25-22	Downgrade	Goldman	Neutral → Sell	$5
Apr-13-22	Initiated	RBC Capital Mkts	Outperform	$31
Jan-28-22	Initiated	Goldman	Neutral	$11

Show Previous Ratings

Aug-24-26 08:00AM	Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026 (PR Newswire)
Aug-06-26 08:00AM	Edgewise Therapeutics Reports Second Quarter 2026 Financial Results (PR Newswire)
Jul-13-26 08:30AM	Edgewise Therapeutics Completes Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline (PR Newswire) -9.12%
Jul-07-26 12:52PM	Podcast: Servier describes its M&A and manufacturing strategy amidst deal-making drive (Pharmaceutical Technology) +7.56%
Jul-01-26 08:00AM	Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules (PR Newswire)
04:06PM	Loading…
Jun-16-26 04:06PM	Edgewise Bounds Between Double-Digit Losses And Gain - What's Going On? (Investor's Business Daily)
08:44AM	SpaceX, Rackspace surge premarket; Edgewise Therapeutics, Huntsman fall (Investing.com)
07:00AM	Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM) (PR Newswire)
Jun-03-26 04:01PM	Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules (PR Newswire)
Jun-02-26 05:32AM	Servier to acquire Edgewises muscular dystrophy business for $2.65bn (Pharmaceutical Technology) -7.48%
Jun-01-26 10:13AM	How Edgewise Sweetened Its Coffers By $1.55 Billion, And Removed A Key Overhang (Investor's Business Daily) +17.86%
10:03AM	EWTX Stock Hits Record High Why Servier Is Shelling Out $2.65B For Edgewises Muscular Dystrophy Business (Stocktwits)
08:30AM	Edgewise Therapeutics Announces Sale of Sevasemten for Up to $2.65 Billion, Strengthening Balance Sheet and Centering Company Focus on Cardiovascular Pipeline (PR Newswire)
07:39AM	Servier buys into muscular dystrophy with potentially $2.7B deal (BioPharma Dive)
May-12-26 08:00AM	Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2026 (PR Newswire)
08:00AM	Loading…
May-07-26 08:00AM	Edgewise Therapeutics Reports First Quarter 2026 Financial Results and Advances Clinical Programs in Muscular Dystrophy and Cardiovascular Indications (PR Newswire)
Apr-01-26 08:00AM	Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules (PR Newswire) +5.21%
Mar-10-26 07:00AM	Edgewise Announces Positive Long-Term Sevasemten Data Demonstrating Sustained Functional Stabilization in Becker Muscular Dystrophy Through 3.5 Years of Follow-Up (PR Newswire)
Mar-04-26 08:00AM	Edgewise Therapeutics to Present at the Leerink Global Healthcare Conference on March 11, 2026 (PR Newswire)
Mar-03-26 08:00AM	Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2026 MDA Clinical and Scientific Conference (PR Newswire)
Mar-02-26 09:30AM	Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules (PR Newswire)
Feb-26-26 08:00AM	Edgewise Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results with Strong Progress Across Muscular Dystrophy and Cardiovascular Programs (PR Newswire)
Feb-13-26 04:24PM	Edgewise Therapeutics Teases Phase 3 Sevasemten Readout, HCM Data Update at Guggenheim Conference (MarketBeat)
Feb-05-26 08:00AM	Edgewise Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 12, 2026 (PR Newswire)
Feb-02-26 08:00AM	Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules (PR Newswire)
Jan-15-26 11:35AM	Edgewise Therapeutics, Inc. (EWTX) Outlines Priorities For 2026 (Insider Monkey) -5.57%
Jan-13-26 08:00AM	Edgewise Therapeutics Provides Corporate Updates and Highlights Priorities for 2026 (PR Newswire)
Jan-06-26 08:00AM	Edgewise Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 13, 2026 (PR Newswire)
Jan-05-26 08:00AM	Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules (PR Newswire)
Dec-24-25 06:20PM	Why Edgewise Therapeutics Stock Rocked the Market Today (Motley Fool) +25.50%
08:00AM	Loading…
08:00AM	Edgewise Therapeutics Announces Completion of the EDG-7500 CIRRUS-HCM Phase 2 Parts B and C and Favorable Interim Safety Results from the Ongoing Part D Study in Hypertrophic Cardiomyopathy (PR Newswire)
Dec-02-25 08:00AM	Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules (PR Newswire) -9.06%
Nov-20-25 08:00AM	Edgewise Therapeutics Appoints Commercial Biotech Executive Christopher Martin to its Board of Directors (PR Newswire)
Nov-17-25 01:20PM	Edgewise Therapeutics Stock Earns RS Rating Upgrade (Investor's Business Daily)
Nov-16-25 10:14PM	Edgewise Therapeutics (EWTX) Reports Heightened R&D Activity in Q3 2025 (Insider Monkey)
Nov-12-25 08:00AM	Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules (PR Newswire)
Nov-10-25 08:00AM	Edgewise Therapeutics Announces Appointment of Michael Nofi as Chief Financial Officer, and the Retirement of Current CFO, R. Michael Carruthers (PR Newswire) +6.53%
Nov-07-25 08:00AM	Edgewise Therapeutics to Participate in Upcoming Investor Conferences (PR Newswire)
Nov-06-25 08:00AM	Edgewise Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights (PR Newswire)
Nov-03-25 08:00AM	Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules (PR Newswire)
Oct-20-25 11:08PM	H.C. Wainwright Maintains a Buy on Edgewise Therapeutics (EWTX), Sets a $42 PT (Insider Monkey)
Oct-02-25 04:01PM	Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules (PR Newswire)
08:00AM	Edgewise Therapeutics to Present on Sevasemten for Becker and Duchenne Muscular Dystrophies at the 30th International Annual Congress of the World Muscle Society (PR Newswire)
Sep-18-25 09:55AM	Wall Street Analysts Think Edgewise Therapeutics (EWTX) Could Surge 182%: Read This Before Placing a Bet (Zacks) +11.81%
Sep-03-25 07:23PM	Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules (PR Newswire)
Sep-02-25 09:55AM	Wall Street Analysts Believe Edgewise Therapeutics (EWTX) Could Rally 172.96%: Here's is How to Trade (Zacks)
Aug-07-25 08:00AM	Edgewise Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights (PR Newswire)
Aug-06-25 04:02PM	Edgewise Therapeutics Reports Inducement Grants as permitted by the Nasdaq Listing Rules (PR Newswire)
Jul-30-25 09:40AM	Peloton upgraded, Booking downgraded: Wall Street's top analyst calls (The Fly)
Jul-04-25 02:43AM	Edgewise Therapeutics Reports Positive Results for Muscular Dystrophy Treatment (Insider Monkey)
Jun-28-25 09:25AM	Edgewise Therapeutics price target lowered to $35 from $40 at Wedbush (TipRanks)
Jun-26-25 06:00AM	Edgewise Therapeutics Reports Positive Results on Sevasemten Program for Becker and Duchenne Muscular Dystrophies (PR Newswire) -8.86%
Jun-03-25 08:00AM	Edgewise Therapeutics to Present at the Annual Goldman Sachs Global Healthcare Conference (PR Newswire)
May-19-25 12:00PM	All You Need to Know About Edgewise Therapeutics (EWTX) Rating Upgrade to Buy (Zacks)
May-16-25 05:55PM	Treehouse Foods, GeneDx Holdings See Activist Action (Barrons.com)
May-14-25 09:55AM	Does Edgewise Therapeutics (EWTX) Have the Potential to Rally 174.68% as Wall Street Analysts Expect? (Zacks)
08:00AM	Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 20, 2025 (PR Newswire)
May-08-25 08:00AM	Edgewise Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights (PR Newswire)
May-05-25 07:57AM	Is Edgewise Therapeutics, Inc. (EWTX) the Best Small Cap Stock to Buy with the Biggest Upside Potential? (Insider Monkey)
May-02-25 07:07PM	Why Edgewise Therapeutics Stock Popped This Week (Motley Fool)
Apr-25-25 04:31PM	Is Edgewise Therapeutics Inc. (NASDAQ:EWTX) the Most Promising Small-Cap Stock According to Analysts? (Insider Monkey) +5.66%
Apr-15-25 06:00AM	Bristol Myers stumbles in bid to widen heart drugs use (BioPharma Dive) +5.60%
Apr-10-25 05:00AM	The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb (Zacks) -7.44%
Apr-09-25 01:45PM	Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More (Zacks) +8.79%
Apr-08-25 09:33PM	Edgewise Therapeutics, Inc. (EWTX): Among Stocks Insiders Bought in April After Trump's Tariff Rollout (Insider Monkey)
Apr-07-25 12:17PM	EWTX Stock Down 48% in a Week Despite Upbeat Cardiomyopathy Study Data (Zacks)
Apr-05-25 05:29PM	Edgewise Therapeutics (EWTX): Among Unstoppable Stocks That Could Double Your Money (Insider Monkey)
Apr-03-25 02:16PM	Edgewise Therapeutics Downgraded Following Safety Issues in Heart Drug Trial (GuruFocus.com) -12.50%
Apr-02-25 04:54PM	Edgewise Therapeutics: Despite AF Safety Issues, EDG-7500 Advancement Presses On (Seeking Alpha) -22.90%
04:36PM	Why Edgewise Therapeutics And Cytokinetics Stocks Just Diverged (Investor's Business Daily)
03:02PM	Edgewise Therapeutics Stock Plummets on Drug Trial 'Adverse Events' (Investopedia)
06:22AM	Edgewise Therapeutics Announces Pricing of $200 Million Underwritten Offering of Common Stock (PR Newswire)
06:00AM	Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) (PR Newswire)
Mar-26-25 04:45PM	Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on Wednesday, April 2 at 8:30 am Eastern Time (PR Newswire) +5.30%
Mar-11-25 08:00AM	Edgewise Therapeutics to Present on Sevasemten for the Treatment of Becker Muscular Dystrophy at the 2025 MDA Clinical and Scientific Conference (Business Wire)
Mar-04-25 08:00AM	Edgewise Therapeutics to Present at the Leerink Partners Global Healthcare Conference on March 11, 2025 (Business Wire)
Mar-03-25 08:00AM	Edgewise Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights (Business Wire)
Feb-19-25 10:46AM	Should You Invest in Edgewise Therapeutics (EWTX)? (Insider Monkey)
Jan-23-25 01:37AM	Why Is Andreas Halvorsen Bullish On Edgewise Therapeutics, Inc. (EWTX) Now? (Insider Monkey)
Jan-22-25 08:00AM	Edgewise Therapeutics Strengthens Leadership Team to Support Late-Stage Clinical Development (Business Wire)
Jan-13-25 08:00AM	Edgewise Therapeutics Provides Corporate Update and Highlights Priorities for 2025 (Business Wire)
Jan-07-25 08:00AM	Edgewise Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025 (Business Wire)
Dec-16-24 11:56AM	Edgewise Therapeutics' Lead Candidate Reduces Biomarker Levels In Mid-Stage Study In Patients With Muscle Weakness Disease (Benzinga) +18.36%
07:02AM	Edgewise weighs fast approval path for muscular dystrophy drug (BioPharma Dive)
06:00AM	Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker) (Business Wire)
Dec-05-24 02:32PM	Edgewise Provides Statement Regarding Company's Relationship with Dr. Han Phan at Rare Disease Research (Business Wire)
Nov-26-24 06:00AM	Edgewise Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024 (Business Wire)
Nov-07-24 08:00AM	Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights (Business Wire)
Oct-07-24 05:37PM	Edgewise Therapeutics, Inc. (EWTX): A Hot Stock to Buy Now (Insider Monkey)
Oct-01-24 08:00AM	Edgewise Therapeutics to Present on Sevasemten (EDG-5506) for Becker Muscular Dystrophy (Becker) at the 29th International Annual Congress of the World Muscle Society (Business Wire)
Sep-20-24 07:28AM	Novo sinks on obesity drug results; Sanofi reveals anticipated MS data (BioPharma Dive)
04:52AM	Edgewises EDG-7500 shows benefit in two obstructive HCM trials (Clinical Trials Arena)
Sep-19-24 04:08PM	How Edgewise, Up 55%, Is Hoping To Edge Out Bristol, Cytokinetics In Heart Disease (Investor's Business Daily) +54.69%
12:55PM	Why Edgewise Therapeutics Stock Is Up 50% on Thursday (Motley Fool)
09:22AM	Edgewise Catapults On Surprise Victory In Cardiomyopathy; Cytokinetics Shares Dip (Investor's Business Daily)
07:00AM	Edgewise Therapeutics Announces Positive Top-Line Data from Phase 1 Trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) (Business Wire)
Sep-17-24 04:01PM	Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Data from Phase 1 trial in Healthy Subjects and Phase 2 CIRRUS-HCM Trial in Patients with Obstructive Hypertrophic Cardiomyopathy (HCM) on Thursday, September 19 at 8:30 am Eastern Time (Business Wire) +7.21% +5.50%
Aug-08-24 08:00AM	Edgewise Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights (Business Wire)
Jul-30-24 12:25PM	7 Small-Cap Stocks to Buy for Large-Scale Gains (InvestorPlace) -5.49%
Jul-21-24 09:00AM	Dont Be Scared of Heights: J.P. Morgan Suggests 2 Stocks to Buy (TipRanks)

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm focuses on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Its platform utilizes custom-built throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. The company was founded by Badreddin Edris, Alan Russel and Peter A. Thompson in 2017 and is headquartered in Boulder, CO.

M.D.Dr. Peter A. Thompson FACP

PresidentDr. Kevin Koch Ph.D.

Co-Founder & Independent DirectorDr. Badreddin Edris Ph.D.

Co-FounderDr. Alan J. Russell Ph.D.

Chief Financial OfficerMr. Michael P. Nofi

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Donovan Joanne M.	CMO	Aug 12 '26	Option Exercise	0.00	12,812	0	18,066	Aug 14 04:54 PM
Donovan Joanne M.	CMO	Aug 12 '26	Sale	43.85	6,522	286,000	11,544	Aug 14 04:54 PM
Donovan Joanne M.	CMO	Aug 13 '26	Sale	43.41	2,919	126,704	8,625	Aug 14 04:54 PM
Russell Alan J	Chief Scientific Officer	Aug 12 '26	Option Exercise	0.00	12,812	0	37,367	Aug 14 04:53 PM
Russell Alan J	Chief Scientific Officer	Aug 12 '26	Sale	43.73	5,901	258,042	31,466	Aug 14 04:53 PM
MOORE JOHN R	General Counsel	Aug 12 '26	Option Exercise	0.00	12,499	0	22,713	Aug 14 04:53 PM
MOORE JOHN R	General Counsel	Aug 12 '26	Sale	43.82	5,016	219,823	17,697	Aug 14 04:53 PM
Derakhshan Behrad	Chief Business Officer	Aug 12 '26	Option Exercise	0.00	13,281	0	36,926	Aug 14 04:53 PM
Derakhshan Behrad	Chief Business Officer	Aug 12 '26	Sale	43.81	5,100	223,424	31,826	Aug 14 04:53 PM
KOCH KEVIN	President and CEO	Aug 12 '26	Option Exercise	0.00	39,844	0	70,459	Aug 14 04:52 PM
KOCH KEVIN	President and CEO	Aug 12 '26	Sale	43.68	17,971	785,042	52,488	Aug 14 04:52 PM
JOANNE DONOVAN	Officer	Aug 13 '26	Proposed Sale	43.56	2,919	127,152		Aug 13 04:31 PM
Russell Alan J	Chief Scientific Officer	Jul 01 '26	Option Exercise	0.36	200,000	71,195	224,555	Jul 02 05:21 PM
Russell Alan J	Chief Scientific Officer	Jul 01 '26	Sale	39.41	200,000	7,881,402	24,555	Jul 02 05:21 PM
ALAN J RUSSELL	Director	Jul 01 '26	Proposed Sale	40.63	200,000	8,126,000		Jul 01 04:55 PM
JOANNE DONOVAN	Officer	May 05 '26	Proposed Sale	31.45	50,000	1,572,500		May 05 04:29 PM
Donovan Joanne M.	CMO	May 05 '26	Option Exercise	7.08	50,000	354,000	54,367	May 05 01:15 PM
Donovan Joanne M.	CMO	May 05 '26	Sale	38.57	50,000	1,928,400	4,367	May 05 01:15 PM
Donovan Joanne M.	CMO	May 04 '26	Sale	31.29	5,230	163,663	4,367	May 05 01:15 PM
Donovan Joanne M.	CMO	Apr 01 '26	Option Exercise	7.08	28,662	202,927	38,259	Apr 02 01:01 PM
Donovan Joanne M.	CMO	Apr 01 '26	Sale	32.31	28,662	926,095	9,597	Apr 02 01:01 PM
Donovan Joanne M.	CMO	Mar 31 '26	Option Exercise	7.08	21,338	151,073	30,935	Mar 31 07:33 PM
Donovan Joanne M.	CMO	Mar 31 '26	Sale	32.12	21,338	685,308	9,597	Mar 31 07:33 PM
Donovan Joanne M.	CMO	Mar 27 '26	Sale	30.98	16,358	506,735	9,597	Mar 30 05:32 PM
JOANNE DONOVAN	Officer	Mar 27 '26	Proposed Sale	31.65	71,588	2,265,760		Mar 27 04:41 PM
Edris Badreddin	Director	Jan 21 '26	Option Exercise	1.47	115,471	170,264	135,291	Jan 23 01:34 PM
Edris Badreddin	Director	Jan 21 '26	Sale	29.44	115,471	3,399,466	19,820	Jan 23 01:34 PM
Badreddin Edris	Director	Jan 21 '26	Proposed Sale	29.04	115,471	3,353,279		Jan 21 04:05 PM
ROBERT MICHAEL CARRUTHERS	Officer	Jan 20 '26	Proposed Sale	28.11	183,867	5,168,722		Jan 20 04:14 PM
ROBERT MICHAEL CARRUTHERS	Officer	Jan 15 '26	Proposed Sale	26.56	180,872	4,804,322		Jan 15 04:45 PM
ROBERT MICHAEL CARRUTHERS	Officer	Dec 26 '25	Proposed Sale	26.06	116,665	3,039,812		Dec 29 09:06 AM
ROBERT MICHAEL CARRUTHERS	Officer	Nov 17 '25	Proposed Sale	22.38	70,000	1,566,586		Nov 17 04:38 PM
Russell Alan J	Chief Scientific Officer	Nov 12 '25	Option Exercise	0.18	100,000	18,000	123,400	Nov 13 06:06 PM
Russell Alan J	Chief Scientific Officer	Nov 12 '25	Sale	21.12	100,000	2,112,450	23,400	Nov 13 06:06 PM
Fox Jonathan C	Director	Nov 11 '25	Buy	18.64	10,700	199,403	23,702	Nov 13 06:04 PM
ALAN J RUSSELL	Officer	Nov 12 '25	Proposed Sale	21.12	100,000	2,112,450		Nov 12 04:58 PM

SION

Sionna Therapeutics Inc

CRVS

Corvus Pharmaceuticals Inc

EWTX

Edgewise Therapeutics Inc

Upgrade your Finviz experience